Tech Company Financing Transactions
Symbiomix Therapeutics Funding Round
Symbiomix Therapeutics closed a $41 million Series A investment round on 5/6/2015. Backers included F-Prime Capital, HBM Healthcare Investments and OrbiMed.
Transaction Overview
Company Name
Announced On
5/6/2015
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$41,000,000
Round
Series A
Proceeds Purpose
The funds will be used to advance SYM-1219 through Phase 3 and towards the filing of an NDA.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
105 Lock St. 409
Newark, NJ 07103
USA
Newark, NJ 07103
USA
Phone
Website
Email Address
Not Recorded
Overview
Symbiomix Therapeutics is a biopharmaceutical company developing innovative medicines for serious women's health infections that have been long neglected and are in need of new therapeutic options.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Klaus Veitinger
Chief Financial Officer
Robert Jacks
Chief Medical Officer
Carol Braun
Chief Scientific Officer
Helen Pentikis
VP - Operations
Nikki Adetoro
Browse more venture capital transactions:
Prev: 5/6/2015: DrFirst venture capital transaction
Next: 5/6/2015: Wonder Workshop venture capital transaction
Share this article
Where The Data Comes From
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs